Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Dec 1;100(11):2849–2857. doi: 10.1172/JCI119833

Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation.

X Jin 1, R K Shepherd 1, B R Duling 1, J Linden 1
PMCID: PMC508491  PMID: 9389751

Abstract

We investigated the mechanism by which inosine, a metabolite of adenosine that accumulates to > 1 mM levels in ischemic tissues, triggers mast cell degranulation. Inosine was found to do the following: (a) compete for [125I]N6-aminobenzyladenosine binding to recombinant rat A3 adenosine receptors (A3AR) with an IC50 of 25+/-6 microM; (b) not bind to A1 or A2A ARs; (c) bind to newly identified A3ARs in guinea pig lung (IC50 = 15+/-4 microM); (d) lower cyclic AMP in HEK-293 cells expressing rat A3ARs (ED50 = 12+/-5 microM); (e) stimulate RBL-2H3 rat mast-like cell degranulation (ED50 = 2.3+/-0.9 microM); and (f) cause mast cell-dependent constriction of hamster cheek pouch arterioles that is attenuated by A3AR blockade. Inosine differs from adenosine in not activating A2AARs that dilate vascular smooth muscle and inhibit mast cell degranulation. The A3 selectivity of inosine may explain why it elicits a monophasic arteriolar constrictor response distinct from the multiphasic dilator/constrictor response to adenosine. Nucleoside accumulation and an increase in the ratio of inosine to adenosine may provide a physiologic stimulus for mast cell degranulation in ischemic or inflamed tissues.

Full Text

The Full Text of this article is available as a PDF (283.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asano T., Ogasawara N. Uncoupling of gamma-aminobutyric acid B receptors from GTP-binding proteins by N-ethylmaleimide: effect of N-ethylmaleimide on purified GTP-binding proteins. Mol Pharmacol. 1986 Mar;29(3):244–249. [PubMed] [Google Scholar]
  2. Brooker G., Terasaki W. L., Price M. G. Gammaflow: a completely automated radioimmunoassay system. Science. 1976 Oct 15;194(4262):270–276. doi: 10.1126/science.184530. [DOI] [PubMed] [Google Scholar]
  3. Church M. K., Hughes P. J. Adenosine potentiates immunological histamine release from rat mast cells by a novel cyclic AMP-independent cell-surface action. Br J Pharmacol. 1985 May;85(1):3–5. doi: 10.1111/j.1476-5381.1985.tb08823.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Deussen A., Bading B., Kelm M., Schrader J. Formation and salvage of adenosine by macrovascular endothelial cells. Am J Physiol. 1993 Mar;264(3 Pt 2):H692–H700. doi: 10.1152/ajpheart.1993.264.3.H692. [DOI] [PubMed] [Google Scholar]
  5. Doyle M. P., Linden J., Duling B. R. Nucleoside-induced arteriolar constriction: a mast cell-dependent response. Am J Physiol. 1994 May;266(5 Pt 2):H2042–H2050. doi: 10.1152/ajpheart.1994.266.5.H2042. [DOI] [PubMed] [Google Scholar]
  6. Ehlert F. J. Allosterism and drug action. Proc West Pharmacol Soc. 1992;35:215–219. [PubMed] [Google Scholar]
  7. Felgner P. L., Gadek T. R., Holm M., Roman R., Chan H. W., Wenz M., Northrop J. P., Ringold G. M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7413–7417. doi: 10.1073/pnas.84.21.7413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fozard J. R., Carruthers A. M. Adenosine A3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat. Br J Pharmacol. 1993 May;109(1):3–5. doi: 10.1111/j.1476-5381.1993.tb13522.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hughes P. J., Benyon R. C., Church M. K. Adenosine inhibits immunoglobulin E-dependent histamine secretion from human basophil leukocytes by two independent mechanisms. J Pharmacol Exp Ther. 1987 Sep;242(3):1064–1070. [PubMed] [Google Scholar]
  10. Hughes P. J., Church M. K. Separate purinoceptors mediate enhancement by adenosine of concanavalin A-induced mediator release and the cyclic AMP response in rat mast cells. Agents Actions. 1986 Apr;18(1-2):81–84. doi: 10.1007/BF01987989. [DOI] [PubMed] [Google Scholar]
  11. Hughes P. J., Holgate S. T., Church M. K. Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. Biochem Pharmacol. 1984 Dec 1;33(23):3847–3852. doi: 10.1016/0006-2952(84)90050-9. [DOI] [PubMed] [Google Scholar]
  12. Jennings R. B., Steenbergen C., Jr Nucleotide metabolism and cellular damage in myocardial ischemia. Annu Rev Physiol. 1985;47:727–749. doi: 10.1146/annurev.ph.47.030185.003455. [DOI] [PubMed] [Google Scholar]
  13. Jones C. E., Thomas J. X., Jr, Devous M. D., Norris C. P., Smith E. E. Positive inotropic response to inosine in the in situ canine heart. Am J Physiol. 1977 Oct;233(4):H438–H443. doi: 10.1152/ajpheart.1977.233.4.H438. [DOI] [PubMed] [Google Scholar]
  14. Keller A. M., Clancy R. M., Barr M. L., Marboe C. C., Cannon P. J. Acute reoxygenation injury in the isolated rat heart: role of resident cardiac mast cells. Circ Res. 1988 Dec;63(6):1044–1052. doi: 10.1161/01.res.63.6.1044. [DOI] [PubMed] [Google Scholar]
  15. Linden J. Adenosine deaminase for removing adenosine: how much is enough? Trends Pharmacol Sci. 1989 Jul;10(7):260–262. doi: 10.1016/0165-6147(89)90021-7. [DOI] [PubMed] [Google Scholar]
  16. Linden J. Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci. 1994 Aug;15(8):298–306. doi: 10.1016/0165-6147(94)90011-6. [DOI] [PubMed] [Google Scholar]
  17. Linden J., Patel A., Sadek S. [125I]Aminobenzyladenosine, a new radioligand with improved specific binding to adenosine receptors in heart. Circ Res. 1985 Feb;56(2):279–284. doi: 10.1161/01.res.56.2.279. [DOI] [PubMed] [Google Scholar]
  18. Linden J., Taylor H. E., Robeva A. S., Tucker A. L., Stehle J. H., Rivkees S. A., Fink J. S., Reppert S. M. Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol Pharmacol. 1993 Sep;44(3):524–532. [PubMed] [Google Scholar]
  19. Lohse M. J., Maurer K., Gensheimer H. P., Schwabe U. Dual actions of adenosine on rat peritoneal mast cells. Naunyn Schmiedebergs Arch Pharmacol. 1987 May;335(5):555–560. doi: 10.1007/BF00169124. [DOI] [PubMed] [Google Scholar]
  20. Lohse M. J., Maurer K., Klotz K. N., Schwabe U. Synergistic effects of calcium-mobilizing agents and adenosine on histamine release from rat peritoneal mast cells. Br J Pharmacol. 1989 Dec;98(4):1392–1398. doi: 10.1111/j.1476-5381.1989.tb12689.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Luthin D. R., Olsson R. A., Thompson R. D., Sawmiller D. R., Linden J. Characterization of two affinity states of adenosine A2a receptors with a new radioligand, 2-[2-(4-amino-3-[125I]iodophenyl)ethylamino]adenosine. Mol Pharmacol. 1995 Feb;47(2):307–313. [PubMed] [Google Scholar]
  22. Martin P. L. Relative agonist potencies of C2-substituted analogues of adenosine: evidence for adenosine A2B receptors in the guinea pig aorta. Eur J Pharmacol. 1992 Jun 5;216(2):235–242. doi: 10.1016/0014-2999(92)90365-b. [DOI] [PubMed] [Google Scholar]
  23. Martin P. L., Wysocki R. J., Jr, Barrett R. J., May J. M., Linden J. Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. J Pharmacol Exp Ther. 1996 Feb;276(2):490–499. [PubMed] [Google Scholar]
  24. Ott I., Lohse M. J., Klotz K. N., Vogt-Moykopf I., Schwabe U. Effects of adenosine on histamine release from human lung fragments. Int Arch Allergy Immunol. 1992;98(1):50–56. doi: 10.1159/000236163. [DOI] [PubMed] [Google Scholar]
  25. Ramkumar V., Stiles G. L., Beaven M. A., Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem. 1993 Aug 15;268(23):16887–16890. [PubMed] [Google Scholar]
  26. Sakai K., Akima M. Vasoconstriction after adenosine and inosine in the rat isolated hindlimb abolished by blockade of tryptaminergic mechanisms. Naunyn Schmiedebergs Arch Pharmacol. 1978 Mar;302(1):55–59. doi: 10.1007/BF00586597. [DOI] [PubMed] [Google Scholar]
  27. Salvatore C. A., Jacobson M. A., Taylor H. E., Linden J., Johnson R. G. Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10365–10369. doi: 10.1073/pnas.90.21.10365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Schwartz L. B., Austen K. F., Wasserman S. I. Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J Immunol. 1979 Oct;123(4):1445–1450. [PubMed] [Google Scholar]
  29. Shearman L. P., Weaver D. R. [125I]4-aminobenzyl-5'-N-methylcarboxamidoadenosine (125I)AB-MECA) labels multiple adenosine receptor subtypes in rat brain. Brain Res. 1997 Jan 16;745(1-2):10–20. doi: 10.1016/s0006-8993(96)01120-1. [DOI] [PubMed] [Google Scholar]
  30. Shepherd R. K., Linden J., Duling B. R. Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Circ Res. 1996 Apr;78(4):627–634. doi: 10.1161/01.res.78.4.627. [DOI] [PubMed] [Google Scholar]
  31. Stowell C. P., Kuhlenschmidt T. B., Hoppe C. A. A fluorescamine assay for submicrogram quantities of protein in the presence of Triton X-100. Anal Biochem. 1978 Apr;85(2):572–580. doi: 10.1016/0003-2697(78)90256-7. [DOI] [PubMed] [Google Scholar]
  32. Zhou Q. Y., Li C., Olah M. E., Johnson R. A., Stiles G. L., Civelli O. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7432–7436. doi: 10.1073/pnas.89.16.7432. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES